Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone

• Published in: Bone (New York, N.Y.) N.Y.), 2011-06, Vol.48 (6), p.1354-1361
• Main Authors: Li, Xin, Liao, Jinhui, Park, Serk In, Koh, Amy J, Sadler, William D, Pienta, Kenneth J, Rosol, Thomas J, McCauley, Laurie K
• Format: Article
• Language: English
• Subjects: Animals; Biological and medical sciences; Bone and Bones - drug effects; Bone and Bones - metabolism; Bone Density Conservation Agents - pharmacology; Calcium - metabolism; Cell Division - drug effects; Cell Line, Tumor; Diphosphonates - pharmacology; Dogs; Fundamental and applied biological sciences. Psychology; Gynecology. Andrology. Obstetrics; Imidazoles - pharmacology; Male; Male genital diseases; Medical sciences; Mice; Mice, Nude; Nephrology. Urinary tract diseases; Orthopedics; Osteoclasts - drug effects; Prostatic Neoplasms - pathology; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Vertebrates: anatomy and physiology, studies on body, several organs or systems
• ISSN: 8756-3282; 1873-2763
• DOI: 10.1016/j.bone.2011.03.687

Abstract Prostate carcinoma frequently metastasizes to bone where the microenvironment facilitates its growth. Inhibition of bone resorption is effective in reducing tumor burden and bone destruction in prostate cancer. However, whether drugs that inhibit osteoclast function inhibit tumor growth independent of inhibition of bone resorption is unclear. Calcium is released during bone resorption and the calcium sensing receptor is an important regulator of cancer cell proliferation. The goal of this investigation was to elucidate the role of calcium released during bone resorption and to determine the impact of drugs which suppress bone resorption on tumor growth in bone. To compare tumor growth in a skeletal versus non-skeletal site, equal numbers of canine prostate cancer cells expressing luciferase (ACE-1luc ) were inoculated into a simple collagen matrix, neonatal mouse vertebrae (vossicles), human de-proteinized bone, or a mineralized collagen matrix. Implants were placed subcutaneously into athymic mice. Luciferase activity was used to track tumor growth weekly, and at one month tumors were dissected for histologic analysis. Luciferase activity and tumor size were greater in vossicles, de-proteinized bone and mineralized collagen matrix versus non-mineralized collagen implants. The human osteoblastic prostate carcinoma cell line C4-2b also grew better in a mineral rich environment with a greater proliferation of C4-2b cells reflected by Ki-67 staining. Zoledronic acid (ZA), a bisphosphonate, and recombinant OPG-Fc, a RANKL inhibitor, were administered to mice bearing vertebral implants (vossicles) containing ACE-1 osteoblastic prostate cancer cells. Vossicles or collagen matrices were seeded with ACE-1luc cells subcutaneously in athymic mice (2 vossicles, 2 collagen implants/mouse). Mice received ZA (5 μg/mouse, twice/week), (OPG-Fc at 10 mg/kg, 3 times/week) or vehicle, and luciferase activity was measured weekly. Histologic analysis of the tumors, vossicles and endogenous bones and serum biochemistry were performed. Antiresorptive administration was associated with decreased serum TRAP5b, reduced osteoclast numbers, and increased tibia and vossicle bone areas. ZA significantly decreased bone marrow calcium concentrations without affecting serum calcium. ZA and OPG-Fc significantly inhibited tumor growth in bone but not in collagen implants. In conclusion, the inhibitory effects of ZA or OPG-Fc on prostate tumor growth in bone are mediated via blockin